- call +1-201-465-4211
- email sales@mrinsights.biz
Non-Hodgkin lymphoma (NHL) is a condition where abnormal lymphocytes are produced in the human body. These lymphocytes do not die and keep growing and dividing within the body unless treated. NHL is generally located at lymph nodes, however, if not treated in time then it might spread to the entire lymphatic system.
Scope of the Report:
Factors such as demand for innovative drugs and novel technologies, FDA's approval for chronic lymphocytic leukemia therapy drugs, introduction of promising drugs such as novel small molecule inhibitors and next-generation monoclonal antibodies, and increase in prevalence of NHL drives the market growth.
However, high cost of the vaccines used in NHL therapy and side-effects associated with them restrain the market growth.
Moreover, introduction of newer biologics in the NHL market, patent expiry of standard drugs in untapped market provide numerous opportunities regarding healthcare in near future.
The global Non-Hodgkin Lymphoma Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Non-Hodgkin Lymphoma Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Non-Hodgkin Lymphoma Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Non-Hodgkin Lymphoma Therapeutics market by product type and applications/end industries.
Market Segment by Companies, this report covers
Bristol Myers Squibb
Celgene
Eli Lilly
F. Hoffman La-Roche
GlaxoSmithKline
Accredo Health Group
Baxter International
Bayer
Cephalon
Eisai Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Chemotherapy
Targeted Therapy
Market Segment by Applications, can be divided into
Clinical Research
Treatment
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Non-Hodgkin Lymphoma Therapeutics Market Overview
1.1 Product Overview and Scope of Non-Hodgkin Lymphoma Therapeutics
1.2 Classification of Non-Hodgkin Lymphoma Therapeutics by Types
1.2.1 Global Non-Hodgkin Lymphoma Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Types in 2017
1.2.3 Chemotherapy
1.2.4 Targeted Therapy
1.3 Global Non-Hodgkin Lymphoma Therapeutics Market by Application
1.3.1 Global Non-Hodgkin Lymphoma Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Clinical Research
1.3.3 Treatment
1.4 Global Non-Hodgkin Lymphoma Therapeutics Market by Regions
1.4.1 Global Non-Hodgkin Lymphoma Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Non-Hodgkin Lymphoma Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Non-Hodgkin Lymphoma Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-Hodgkin Lymphoma Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Non-Hodgkin Lymphoma Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-Hodgkin Lymphoma Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Non-Hodgkin Lymphoma Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Bristol Myers Squibb
2.1.1 Business Overview
2.1.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Celgene
2.2.1 Business Overview
2.2.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Celgene Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Eli Lilly
2.3.1 Business Overview
2.3.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 F. Hoffman La-Roche
2.4.1 Business Overview
2.4.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 GlaxoSmithKline
2.5.1 Business Overview
2.5.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Accredo Health Group
2.6.1 Business Overview
2.6.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Baxter International
2.7.1 Business Overview
2.7.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Baxter International Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Bayer
2.8.1 Business Overview
2.8.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Bayer Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Cephalon
2.9.1 Business Overview
2.9.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Cephalon Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Eisai Pharmaceuticals
2.10.1 Business Overview
2.10.2 Non-Hodgkin Lymphoma Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Non-Hodgkin Lymphoma Therapeutics Market Competition, by Players
3.1 Global Non-Hodgkin Lymphoma Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-Hodgkin Lymphoma Therapeutics Players Market Share
3.2.2 Top 10 Non-Hodgkin Lymphoma Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Non-Hodgkin Lymphoma Therapeutics Market Size by Regions
4.1 Global Non-Hodgkin Lymphoma Therapeutics Revenue and Market Share by Regions
4.2 North America Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Non-Hodgkin Lymphoma Therapeutics Revenue by Countries
5.1 North America Non-Hodgkin Lymphoma Therapeutics Revenue by Countries (2013-2018)
5.2 USA Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Countries
6.1 Europe Non-Hodgkin Lymphoma Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Countries
7.1 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue by Countries (2013-2018)
7.2 China Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Non-Hodgkin Lymphoma Therapeutics Revenue by Countries
8.1 South America Non-Hodgkin Lymphoma Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Non-Hodgkin Lymphoma Therapeutics by Countries
9.1 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Non-Hodgkin Lymphoma Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Non-Hodgkin Lymphoma Therapeutics Market Segment by Type
10.1 Global Non-Hodgkin Lymphoma Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Non-Hodgkin Lymphoma Therapeutics Market Forecast by Type (2018-2023)
10.3 Chemotherapy Revenue Growth Rate (2013-2023)
10.4 Targeted Therapy Revenue Growth Rate (2013-2023)
11 Global Non-Hodgkin Lymphoma Therapeutics Market Segment by Application
11.1 Global Non-Hodgkin Lymphoma Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Non-Hodgkin Lymphoma Therapeutics Market Forecast by Application (2018-2023)
11.3 Clinical Research Revenue Growth (2013-2018)
11.4 Treatment Revenue Growth (2013-2018)
12 Global Non-Hodgkin Lymphoma Therapeutics Market Size Forecast (2018-2023)
12.1 Global Non-Hodgkin Lymphoma Therapeutics Market Size Forecast (2018-2023)
12.2 Global Non-Hodgkin Lymphoma Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Non-Hodgkin Lymphoma Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Non-Hodgkin Lymphoma Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Non-Hodgkin Lymphoma Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Non-Hodgkin Lymphoma Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Non-Hodgkin Lymphoma Therapeutics Picture
Table Product Specifications of Non-Hodgkin Lymphoma Therapeutics
Table Global Non-Hodgkin Lymphoma Therapeutics and Revenu
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
